08:26 AM EDT, 05/14/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Tuesday the US Food and Drug Administration granted priority review for its biologics license application for gene therapy Upstaza.

The application was given a target regulatory action date of Nov. 13, PTC said.

Upstaza is a one-time gene replacement therapy for aromatic L-amino acid decarboxylase, or AADC, deficiency in patients 18 months and older, according to PTC.

Shares of the company were up 5% in recent Tuesday premarket activity.

Price: 33.29, Change: +1.59, Percent Change: +5.02